8-chloro-adenosine, an RNA-directed nucleoside analog, may prove a promising target with a unique mechanism of action for patients with relapsed or refractory acute myeloid leukemia (AML).
Previous activity has been demonstrated in a number of solid tumors and hematological malignancies, and now principal investigator Vinod Pullarkat, M.D., from City of Hope is opening the first-in-man investigation of the new therapeutic approach in poor-risk AML.
Unlike other nucleoside analogs used to treat AML, 8-chloro-adenosine inhibits RNA synthesis within AML cells in a dose-dependent manner. The unique RNA and ATP-targeting mechanism of action will first be evaluated in single-agent studies, with the potential for synergistic effects with Bcl-2 inhibitors in future research.
The phase I/II dose-finding study evaluating 8-chloro-adenosine as a single agent is now open for recruitment for patients who have:
- Relapsed AML after failure on at least one line of salvage therapy
- De novo AML and have not achieved complete remission after two lines of therapy
- AML evolving from myelodysplastic syndrome or myeloproliferative disorder and have failed a hypomethylating agent or induction chemotherapy
- Relapsed after allogeneic hematopoietic cell transplant
8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02509546)
For enrollment information in this study, please contact Vinod Pullarkat, M.D., by phone at 626-256-4673.